

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10624-049-999

APPLICATION NO

10/004,642

APPLICANT

Kois et al.

FILING DATE

December 4, 2001

GROUP

1624

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|----|-----------------|------------------|---------|-------|----------|-------------|
| | | | | | | YES NO |
| DG | WO 99/53927 | October 29, 1999 | PCT | — | — | |
| DH | WO 02/085396 | October 31, 2002 | PCT | — | — | |


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|---|
| DI | Spiegelman et al., "Regulation of Adipocyte Gene Expression in Differentiation and Syndromes of Obesity/Diabetes", <i>J. of Biol. Chem.</i> 268:6823-6826 (1993). |
| DJ | Hirosumi et al., "A central role for JNK in obesity and insulin resistance", <i>Letters to Nature</i> 420:333-336 (2002). |
| | |
| | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



| | | |
|--|----------------------------------|------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY DOCKET NO. 10624-049-999 | APPLICATION NO 10/004,642 |
| | APPLICANT Kois et al. | |
| | FILING DATE December 4, 2001 | GROUP 1624 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|----|-----------------|---------|---------|-------|----------|-------------|
| | | | | | | YES NO |
| BE | WO 99/01439 | 1/14/99 | PCT | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|--|
| BF | Aspenstrom et al., 1996, "Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome", <i>Curr. Biol.</i> 6:70-77 |
| BG | Baeuerle and Baichwal, 1997, "NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules", <i>Advances in Immunology</i> 65:111-137 |
| CG | Manning et al., 1997, "Transcription inhibitors in inflammation", <i>Exp. Opin. Invest. Drugs</i> 6:555-567 |
| CL | Nishina et al., 1997, "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes", <i>J. Exp. Med.</i> 186:941-953 |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

Express Mail No.: EL 500 575 856 US

SEP 10 2002

TECH CENTER

| | |
|-----------------------------------|-------------------------------|
| ATTY. DOCKET NO. 10824-049-999 | APPLICATION NO. 10/004,642 |
|-----------------------------------|-------------------------------|

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

| |
|------------------------|
| APPLICANT KOSCIUSKO |
|------------------------|

| | |
|---------------------------------|--------------------|
| FILING DATE December 4, 2001 | GROUP 1614-1624 |
|---------------------------------|--------------------|

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|--|--|
| | | |
| | | |

EXAMINER

[Signature]

DATE CONSIDERED

12-14-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail No.: EL 500 575 025 US

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10624-049-999

APPLICATION NO.

10/004,642

APPLICANT

Kois et al.

FILING DATE

December 4, 2001

GROUP

1624

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|----------|------------------|-------|----------|----------------------------|
| | AA | 4,788,195 | 11/29/88 | Torley et al. | 514 | 252 | |
| | AB | 4,876,252 | 10/24/89 | Torley et al. | 514 | 224.8 | |
| | AC | 4,966,622 | 10/30/90 | Rempfler et al. | 71 | 92 | |
| | AD | 4,973,690 | 11/27/90 | Rempfler et al. | 514 | 279 | |
| | AE | 5,159,078 | 10/27/92 | Rempfler et al. | 544 | 330 | |
| | AF | 5,166,047 | 11/24/92 | Hioki et al. | 430 | 573 | |
| | AG | 5,262,527 | 11/16/93 | Gregory et al. | 534 | 797 | |
| | AH | 5,489,505 | 2/6/96 | Kato et al. | 430 | 584 | |
| | AI | 5,516,775 | 5/14/96 | Zimmerman et al. | 514 | 224.2 | |
| | AJ | 5,527,914 | 6/18/96 | Hioli et al. | 548 | 150 | |
| | AK | 5,942,384 | 8/24/99 | Arai et al. | 430 | 603 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|----|-----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| | AL | WO 98/18782 | 5/7/98 | PCT | — | — | | |
| | AM | WO 01/14375 | 3/1/01 | PCT | — | — | | |
| | AN | WO 01/27089 | 4/19/01 | PCT | — | — | | |
| | AO | WO 00/43373 | 7/27/00 | PCT | — | — | | |
| | AP | WO 98/20003 | 5/14/98 | PCT | — | — | | |
| | AQ | WO 93/08167 | 4/29/93 | PCT | — | — | | |
| | AR | WO 01/12621 | 2/22/01 | PCT | — | — | | |
| | AS | WO 00/75118 | 12/14/00 | PCT | — | — | | |
| | AT | WO 00/39101 | 7/6/00 | PCT | — | — | | |
| | AU | WO 00/56738 | 9/28/00 | PCT | — | — | | |
| | AV | WO 00/15657 | 3/23/00 | PCT | — | — | | |
| | AW | WO 01/91749 | 12/6/01 | PCT | — | — | | |
| | AX | WO 00/12486 | 3/9/00 | PCT | — | — | | |
| | AY | WO 01/29009 | 4/26/01 | PCT | — | — | | |
| | AZ | WO 01/23382 | 4/5/01 | PCT | — | — | | |
| | BA | WO 00/78731 | 12/28/00 | PCT | — | — | | |
| | BB | WO 00/33844 | 6/15/00 | PCT | — | — | | |
| | BC | WO 00/31067 | 6/2/00 | PCT | — | — | | |
| | BD | WO 99/63821 | 12/16/99 | PCT | — | — | | |

| | | | | | | | |
|---|---|---------|-----|--|--|--|--|
| BE | WO 99/01439 | 1/14/99 | PCT | | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| BH | Aspenstrom et al., 1996, "Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome", <i>Curr. Biol.</i> 6:70-77 | | | | | | |
| BG | Baeuerle and Baichwal, 1997, "NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules", <i>Advances in Immunology</i> 65:111-137 | | | | | | |
| BH | Beg et al., 1995, "Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B", <i>Nature</i> 376(6536):167-70 | | | | | | |
| BI | Bohrer et al., 1997, "Role of NFkappaB in the mortality of sepsis.", <i>J. Clin. Inv.</i> 100:972-985 | | | | | | |
| BJ | Brand et al., 1997, "Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion", <i>J Clin Inv.</i> 97:1715-1722 | | | | | | |
| BK | Burke et al., 1999, "Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epsilon as probes of the two catalytic subunits of IkappaB kinase, IKK-1 and IKK-2", <i>Journal of Biological Chemistry</i> 274:36146-36152 | | | | | | |
| BL | Chen et al., 1996, "Activation and inhibition of the AP-1 complex in human breast cancer cells", <i>Mol. Carcinogenesis</i> 15:215-226 | | | | | | |
| BM | Cramer et al., 1999, "A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappaB complex", <i>Structure</i> 7:R1-R6 | | | | | | |
| BN | Deacon et al., 1999, "MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases", <i>J. Biol. Chem.</i> 274:16604-16610 | | | | | | |
| BO | Delhase et al., 1999, "Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation", <i>Science</i> 284:309-313 | | | | | | |
| BP | Dong et al., 1998, "Defective T cell differentiation in the absence of Jnk1", <i>Science</i> 282:2092-2095 | | | | | | |
| BQ | Faris et al., 1996, "Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells", <i>J. Biol. Chem.</i> 271:27366-27373 | | | | | | |
| BR | Gosset et al., 1995, "Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients", <i>Int Arch Allergy Immunol.</i> 106:69-77 | | | | | | |
| BS | Gum et al., 1997, "Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades", <i>Oncogene</i> 14:1481-1493 | | | | | | |
| BT | Han et al., 1999, "Jun N-terminal kinase in rheumatoid arthritis", <i>J. Pharm. Exp. Therap.</i> 291:124-130 | | | | | | |
| BU | Hibi et al., 1993, "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain", <i>M. Genes Dev.</i> 7:2135-2148 | | | | | | |
| BV | Hu et al., 1999, "Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase", <i>Science</i> 284:316-320 | | | | | | |
| BW | Ishizuka et al., 1997, "Mast cell tumor necrosis factor alpha production is regulated by MEK kinases", <i>Proc. Nat. Acad. Sci. USA</i> 94:6358-6363 | | | | | | |
| BX | Karin et al., 1997, "AP-1 function and regulation", <i>Curr Opin Cell Biol</i> 9:240-246. | | | | | | |
| BY | Koch et al., 1995, "Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1", <i>Nature</i> 376:517-519 | | | | | | |
| BZ | Lange-Carter et al., 1993, "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.", <i>Science</i> 260:315-319 | | | | | | |
| CA | Li et al., 1996, "The Ras-JNK pathway is involved in shear-induced gene expression", <i>Mol. Cell. Biol.</i> 16:5947-5954 | | | | | | |
| CB | Li et al., 1999, "IKK1-deficient mice exhibit abnormal development of skin and skeleton", <i>Genes & Development</i> 13:1322-1328 | | | | | | |
| CC | Li et al., 1999, "Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.", <i>Science</i> 284:321-324 | | | | | | |
| CD | Li et al., 1996, "Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells", <i>Science</i> 271: 1272-1276 | | | | | | |
| CE | Lin et al., 1995, "Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2", <i>Science</i> 268:286-289 | | | | | | |
| CF | Malinin et al., 1997, MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1", <i>Nature</i> 385:540-544 | | | | | | |
| CG | Manning et al., "Transcription inhibitors in inflammation", <i>Exp. Opin. Invest. Drugs</i> 6: 555-567 <i>no year</i> | | | | | | |
| CH | Mercurio et al., 1999, "IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex", <i>Mol Cell Biol.</i> 19:1526-1538 | | | | | | |
| CI | Mercurio et al., 1997, "IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation", <i>Science</i> 278:860-866 | | | | | | |
| CJ | Milne et al., 1995, "p53 is phosphorylated <i>in vitro</i> and <i>in vivo</i> by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1", <i>J. Biol. Chem.</i> 270:5511-5518 | | | | | | |
| CK | Mohit et al., 1995, "p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system", <i>C.A. Neuron</i> 14:67-75 | | | | | | |

| | | |
|--------------|--|---|
| AUG 7 9 2002 | | Nishina et al., 1997, "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes", <i>J. Exp. Med.</i> 186:941-953 |
| | | Okamoto et al., 1997, "Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes", <i>Arth & Rheum</i> 40: 919-926 |
| CN | | Paness et al., 1995, "Regional differences in constitutive and induced ICAM-1 expression in vivo", <i>Am J Physiol.</i> 269:H1955-H1964 |
| CO | | Peet and Li, 1999, "kappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin", <i>Journal of Biological Chemistry</i> 274:32655-32661 |
| CP | | Pombo et al., 1994, "The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion", <i>J. Biol. Chem.</i> 269:26546-26551 |
| CQ | | Raitano et al., 1995, "The <i>Bcr-Abl</i> leukemia oncogene activates Jun kinase and requires Jun for transformation", <i>Proc. Natl. Acad. Sci USA</i> 92:11746-11750 |
| CR | | Sabapathy et al., 1999, "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development", <i>Curr Biol</i> 9:116-125 |
| CS | | Su et al., 1994, "JNK is involved in signal integration during costimulation of T lymphocytes", <i>Cell</i> 77:727-736 |
| CT | | Swanek et al., 1997, "Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK", <i>Mol. Cell. Biol.</i> 17:6274-6282 |
| CU | | Szabo et al., "Altered cJUN expression: an early event in human lung carcinogenesis" <i>Cancer Res.</i> 56:305-315, 1996 |
| CV | | Takeda et al., 1999, "Limb and Skin Abnormalities in Mice Lacking IKK α ", <i>Science</i> 284:313-316, 1999 |
| CW | | Tanaka et al., 1999, "Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice", <i>immunity</i> 10:421-429 |
| CX | | Teramoto et al., 1996, "Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family", <i>J. Biol. Chem.</i> 271:27225-27228 |
| CY | | Tournier et al., 1997, "Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase", <i>Proc. Natl. Acad. Sci. USA</i> 94:7337-7342 |
| CZ | | Whitmarsh et al., 1996, "Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways", <i>J. Mol. Med.</i> 74:589-607 |
| DA | | Yan et al., 1994, "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1", <i>Nature</i> 372:798-800 |
| DB | | Yang et al., 1998, "Differentiation of CD4 ⁺ T cells to Th1 cells requires MAP kinase JNK2", <i>Immunity</i> , 9:575-585 |
| DC | | Yaron et al., 1998, "Identification of the receptor component of the IkappaBalpha-ubiquitin ligase", <i>Nature</i> 396:590-594 |
| DD | | Yin et al., "Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney", <i>J. Biol. Chem.</i> 272:19943-19950 |
| DE | | Yujiri et al., 1998, "Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption", <i>Science</i> 282:1911-1914 |
| DF | | Zwacka et al., 1998, "Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation.", <i>Nature Medicine</i> 4:698-704 |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
AUG 30 2002
TECH CENTER 1600/2900